Mineralys’ Phase 3 blood pressure pill data support potential FDA approvalnews2025-03-10T11:01:30+00:00March 10th, 2025|Endpoints News|
Roche launches new research center with Harvard in Boston areanews2025-03-07T15:00:48+00:00March 7th, 2025|Endpoints News|
J&J axes Phase 3 depression program due to ‘insufficient efficacy’ shortly after Neumora’s study failnews2025-03-07T09:43:21+00:00March 7th, 2025|Endpoints News|
Novo Nordisk’s rare disease ‘company within a company’ has an open goal in sickle cellnews2025-03-06T15:57:12+00:00March 6th, 2025|Endpoints News|
Luxa’s stem cell therapy for dry AMD shows early promisenews2025-03-06T15:30:04+00:00March 6th, 2025|Endpoints News|
Denali stops some work on ALS drug after analysis showed no impact on key biomarkernews2025-03-06T14:50:59+00:00March 6th, 2025|Endpoints News|
Novo Nordisk looks into starting GLP-1 drug trials for addictionnews2025-03-06T11:41:28+00:00March 6th, 2025|Endpoints News|
ITM reports more Phase 3 radiopharma data in challenge to Novartis’ Lutatheranews2025-03-06T09:30:41+00:00March 6th, 2025|Endpoints News|
FDA puts BioNTech’s malaria vaccine on clinical holdnews2025-03-05T15:07:53+00:00March 5th, 2025|Endpoints News|
Persica shares early data for antibiotic in chronic back painnews2025-03-05T07:00:08+00:00March 5th, 2025|Endpoints News|
